

Listing of the Claims:

1. (Canceled)
2. (Canceled)
3. (Currently Amended) A method of treating diabetes and/or microvascular diabetic complications comprising administering C-peptide or a pharmaceutical composition comprising C-peptide to a patient once daily; wherein said once daily administration does not include a continuous administration or the presence of release rate-controlling agents, ~~and~~ wherein said administration is by subcutaneous administration, **and wherein said pharmaceutical composition contains 100 to 1800 nmol of C-peptide.**
4. (Canceled)
5. (Canceled)
6. (Canceled)
7. (Canceled)
9. (Canceled)
10. (Previously Amended) The method according to claim 3, wherein said C-peptide is human C-peptide.
11. (Previously Presented) The method according to claim 3, wherein said C-peptide is a fragment EGSLQ (SEQ ID NO: 2).
12. (Previously Amended) The method according to claim 3, wherein said patient is a human.
13. (Canceled)
14. (Previously Amended) The method according to claim 3, wherein said C-peptide is in an aqueous solution.
15. (Currently Amended) The method according to claim 3 ~~and~~ **16**, wherein said complications are diabetic neuropathy.
16. (New) The method according to claim 3, wherein said complications are diabetic nephropathy, retinopathy or neuropathy.